首页> 外国专利> Use of solubilized Klotho, FGF23 and FGFR complex formation mechanism in calcified tissue

Use of solubilized Klotho, FGF23 and FGFR complex formation mechanism in calcified tissue

机译:可溶性Klotho,FGF23和FGFR复合物形成机制在钙化组织中的应用

摘要

Provided are a method for screening an agent for controlling calcification, to which signal transduction relates, common to hard tissue and/or blood vessel; a calcification controlling agent; a method for examining calcification of a bone, calcification of a blood vessel and the pathological advance of a disease accompanying the same; and an examination kit therefor. The method for screening an agent for controlling calcification of hard tissue and/or blood vessel according to the first aspect comprises a step for, in a specimen in the absence and presence of a test compound, contacting soluble Klotho with FGFR and FGF23, and a step for selecting a compound causing a change in the specific signal transduction. The calcification controlling agent according to the second aspect comprises a compound capable of inhibiting or promoting the formation of a soluble Klotho-containing complex. The method for examining calcification according to the third aspect comprises a step for measuring the concentration of soluble Klotho, etc. The kit for examining calcification according to the fourth aspect contains a ligand having binding affinity to soluble Klotho, etc.
机译:本发明提供一种筛选硬组织和/或血管共有的信号转导所涉及的控制钙化的试剂的筛选方法。钙化控制剂;一种检查骨骼钙化,血管钙化和伴随其的疾病的病理进展的方法;并为此准备了一套检查工具。根据第一方面的筛选用于控制硬组织和/或血管钙化的试剂的方法包括以下步骤:在不存在和存在测试化合物的样品中,使可溶性Klotho与FGFR和FGF23接触,以及选择引起特定信号转导变化的化合物的步骤。根据第二方面的钙化控制剂包含能够抑制或促进可溶性含Klotho的络合物的形成的化合物。根据第三方面的用于检查钙化的方法包括测量可溶性Klotho等的浓度的步骤。根据第四方面的用于检查钙化的试剂盒包含对可溶性Klotho等具有结合亲和力的配体。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号